Epidermal growth factor-DNA conjugate for two-step targeting.
International Journal of Oncology
|April 30, 2011
Summary
Researchers developed an epidermal growth factor (EGF) DNA conjugate for targeted cancer therapy. This conjugate selectively binds to cancer cells, internalizes, and releases DNA-binding agents for potential treatment of malignancies.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Malignancies often overexpress the epidermal growth factor (EGF) receptor.
- Targeted drug delivery systems aim to selectively deliver therapeutic agents to cancer cells.
- A two-step targeting strategy involves conjugate binding, internalization, degradation, and release of DNA-binding agents.
Purpose of the Study:
- To develop and evaluate an epidermal growth factor (EGF) DNA conjugate for targeted delivery of DNA-binding compounds.
- To assess the conjugate's ability to bind, internalize, and be retained by human glioma cells overexpressing the EGF receptor.
- To investigate the potential of boronated compounds as DNA-binding agents for cancer therapy.
Main Methods:
- Synthesis of an Iodine-125 labeled EGF (I-125-EGF) DNA conjugate.
- Coupling of I-125-EGF to a 30-mer self-complementary oligonucleotide.
- In vitro evaluation of conjugate binding, internalization, and retention in human glioma cells.
- Characterization of conjugate specificity for the EGF receptor.
Main Results:
- The I-125-EGF-DNA conjugate demonstrated specific binding to the EGF receptor on human glioma cells.
- Efficient internalization and degradation of the conjugate were observed.
- The conjugate exhibited suitable biological properties for targeted delivery applications.
Conclusions:
- The developed I-125-EGF-DNA conjugate shows promise for selective delivery of DNA-binding toxic compounds.
- This conjugate is a viable tool for testing a two-step targeting strategy in cancer therapy.
- Further studies are warranted to explore its therapeutic potential in vivo.
Related Concept Videos
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
01:16TGF - β Signaling Pathway
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...